Downregulation of α‐synuclein in a mouse model of Alzheimer’s Disease: neuropathological, behavioral and transcriptomic changes
Andre Direito Goulart Leitao, Rijwan Uddin Ahammad, Brian Spencer, Chengbiao Wu, Robert A. Rissman · 2025
Read Downregulation of α‐synuclein in a mouse model of Alzheimer’s Disease: neuropathological, behavioral and transcriptomic changes by Andre Direito Goulart Leitao, Rijwan Uddin Ahammad, Brian Spencer, Chengbiao Wu, Robert A. Rissman (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11710809.txt.
Description
Andre Leitao and co-authors lower a brain protein in a mouse model of Alzheimer's disease in a 2025 study. The protein, alpha-synuclein, clumps in Parkinson's disease and is also found in over half of Alzheimer's brains at death. Past work by the team showed benefit from lowering it in these mice.
Treatment used a short DNA-like drug tied to a carrier that crosses the blood-brain barrier. The team tracked brain changes, behavior, and gene activity after dosing. They confirmed the drug reached the brain in the report. Mapping the full response may reveal how this protein shapes Alzheimer's and whether lowering it is a viable therapy.
Catalog record
| CREATOR | Andre Direito Goulart Leitao, Rijwan Uddin Ahammad, Brian Spencer, Chengbiao Wu, Robert A. Rissman |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |